Trials / Terminated
TerminatedNCT00062504
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
A Phase II Trial of Talampanel in Patients With Recurrent High-Grade Gliomas.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To analyze the effect of Talampanel on progression free survival in patients with recurrent high grade gliomas.
Detailed description
To determine the efficacy of Talampanel in patients with recurrent malignant glioma as measured by 6-month progression survival, as well as to obtain preliminary information regarding the spectrum of toxicities of the drug among this patient population.
Conditions
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Mixed Oligoastrocytoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talampanel | 10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2006-01-01
- Completion
- 2006-04-01
- First posted
- 2003-06-12
- Last updated
- 2011-05-23
Source: ClinicalTrials.gov record NCT00062504. Inclusion in this directory is not an endorsement.